ARGX

argenx SE (ARGX)

Last Price$651.40.3%
Market Cap$39.4B
LTM Free Cash Flow
($211.2M)
YoY Growth
-70.8%
3Y CAGR
-27.7%
5Y CAGR
N/A
Stock quality & Intrinsic value
6/10
81.1% overvalued

argenx SE Free Cash Flow

Annual
Quarterly
LTM
Crunching data... Almost there!
Dec'10Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Free Cash Flow
$0.0
($5,974.5K)
($14.4M)
($11.2M)
($8,779.6K)
($17.2M)
$11.3M
($50.1M)
($73.6M)
$116.3M
($493.1M)
($728.2M)
($966.6M)
($464.1M)
ARGX
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for ARGX and see if it's the right time to invest.
Dive in

argenx SE (ARGX) Free Cash Flow comparison analysis

Crunching data... Almost there!

ARGX key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Crunching data... Almost there!

Discover more Stock Ideas

Loved by
investors
worldwide
10K+
Investors use our platform
#1
Top value investing hub with all necessary tools
1K+
Experienced investors in our community
4.9
Average rating across all rating platforms

FAQ

1) What is argenx SE's Free Cash Flow?

As of today, argenx SE's last 12-month Free Cash Flow is ($211.2M), based on the financial report for Sep 30, 2024 (Q3 2024).

2) What is argenx SE's Free Cash Flow growth rate?

Over the last year, argenx SE's Free Cash Flow growth was (70.8%). The average annual Free Cash Flow growth rates for argenx SE have been (14.8%) over the past three years, N/A over the past five years.

3) Is argenx SE's Free Cash Flow growth rate Good?

Over the last year, argenx SE's Free Cash Flow growth was (70.8%), which is lower than industry growth of (0.1%). It indicates that argenx SE's Free Cash Flow growth is Bad.

4) How does argenx SE's Free Cash Flow growth rate compare to its peers?

Over the last year, argenx SE's Free Cash Flow growth was (70.8%), which is lower than peer median growth of (42.0%). The list of peers includes NVO, REGN, BNTX, GMAB, UTHR, INCY, ALNY, BGNE, VRTX, MRNA etc.